In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
Current assets | | | | | | | | |
Cash and cash equivalents | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 |
Accounts receivable | 0.0 | 0.1 | 0.2 | 0.2 | 0.2 | | | |
Prepaid expenses and other assets | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | | |
Income taxes refundable | 0.0 | 0.0 | 0.0 | 0.0 | | | | |
Loan receivable from Emergence Global Enterprises Inc. - related party | | | | | | | | 0.0 |
Total current assets | 0.3 | 0.2 | 0.4 | 0.5 | 0.4 | 0.0 | 0.0 | 0.0 |
|
Other assets | | | | | | | | |
Operating lease right-of-use assets | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | | | |
Other receivable | 0.0 | 0.0 | 0.1 | | | 0.0 | 0.1 | 0.1 |
Note receivable - CEN Biotech Ukraine LLC - related party | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | 0.0 |
Advances to CEN Biotech Ukraine LLC - related party | 1.3 | 1.3 | 1.3 | 1.3 | 1.3 | | | 1.2 |
Property and equipment, net | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | | |
Deferred income taxes | 0.0 | 0.0 | 0.0 | 0.0 | | | | |
Intangible assets, net | -4.8 | -5.0 | -5.0 | -5.1 | 5.3 | 4.7 | 4.8 | -5.0 |
Goodwill | 1.3 | 1.3 | 1.3 | 1.3 | 1.1 | | | |
Total assets | 7.9 | 8.1 | 8.3 | 8.4 | 8.4 | 6.2 | 6.2 | 6.3 |
|
Current liabilities | | | | | | | | |
Accounts payable | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.2 | 0.2 |
Accounts payable – related parties | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 |
Loans payable | 1.7 | 1.7 | 1.7 | 1.7 | 2.0 | 0.8 | 0.5 | 0.5 |
Loans payable – related parties | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 | 1.3 | 1.4 | 1.4 |
Convertible notes payable, net of unamortized discount | 0.8 | 0.7 | 0.6 | 0.6 | 0.7 | 2.1 | 6.8 | 6.7 |
Convertible notes payable, net of unamortized discount - related parties | 0.2 | 0.2 | 0.2 | 0.2 | | | | 2.6 |
Accrued interest | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.3 | 1.2 | 1.1 |
Accrued interest – related parties | 2.0 | 2.0 | 2.0 | 1.9 | 1.8 | | | 1.6 |
Operating lease liabilities | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | | 0.0 |
Governmental assistance payable | 0.1 | 0.1 | 0.1 | 0.1 | | | | |
Accrued expenses | 0.4 | 0.3 | 0.7 | 0.6 | 0.8 | 0.7 | 0.7 | 0.6 |
Total current liabilities | 9.8 | 9.7 | 10.0 | 9.9 | 10.9 | 10.7 | 15.1 | 14.7 |
Operating lease liabilities, less current portion | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | | | 0.1 |
CEBA loan payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | |
Total liabilities | 10.0 | 9.9 | 10.2 | 10.1 | 11.5 | 11.1 | 16.7 | 16.3 |
|
Commitments and contingencies (Notes 4, 11, 12, 18, 19, 24, and 25) | | | | | | | | |
Shareholders’ deficit | | | | | | | | |
Common stock; unlimited authorized shares; 63 | | | | | | | | |
Additional paid-in capital | 44.9 | 44.7 | 44.3 | 44.3 | 40.9 | 38.2 | 17.2 | 17.1 |
Accumulated deficit | -47.0 | -46.6 | -46.2 | -46.0 | -43.9 | -43.2 | -27.7 | -27.1 |
Accumulated other comprehensive loss | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | | |
Total shareholders’ deficit | -2.1 | -1.9 | -1.9 | -1.7 | -3.1 | -5.0 | -10.5 | -10.0 |
Total liabilities and shareholders’ deficit | 7.9 | 8.1 | 8.3 | 8.4 | 8.4 | 6.2 | 6.2 | 6.3 |